![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
EB1089 exhibits a high level of antiproliferative activity against various tumors. However, it is not known whether the mechanism of EB1089 induced the growth inhibition in human hepatic-carcinoma. Here we found that EB1089 significantly reduced cell growth in human hepatoma cells (Hep-G2) and blocked Hep-G2 cell-associated tumor formation in nude mice. The growth inhibition was linked to cell cycle G1 phase arrest by the accumulation of p27 and a reduction of Skp2. Knockdown of Skp2 reversed the p27 induction and G1 arrest. Taken together, our data indicate that EB1089 inhibitory activity is associated with alteration of cell cycle checkpoints through Skp2-dependent p27 induction in Hep-G2 cells.
| ABBREVIATIONS | ||
| FBS | = | fetal bovine serum |
| Skp2 | = | S-phase kinase-associated protein |
| EB1089 | = | 22, 24-diene-24a, 26a,27a-trihomo-1-, 25-dihydroxy-vitamin D3 |
| Hep-G2 | = | human hepatocarcinoma cells |
| ABBREVIATIONS | ||
| FBS | = | fetal bovine serum |
| Skp2 | = | S-phase kinase-associated protein |
| EB1089 | = | 22, 24-diene-24a, 26a,27a-trihomo-1-, 25-dihydroxy-vitamin D3 |
| Hep-G2 | = | human hepatocarcinoma cells |